Classement en actions
#15158
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development... Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Prix de l'action
$3.70
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$369.01M
Changement (1 jour)
0.00%
Échange Hansa Biopharma AB (HNSBF)
Bénéfices pour Hansa Biopharma AB (HNSBF)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Hansa Biopharma AB, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Hansa Biopharma AB de 2026 à 2026
Bénéfices à la fin de chaque année
| Année |
Bénéfices |
Changez |
|
Pas assez de données pour les dates fournies. |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise |
Bénéfices |
Différence de bénéfices |
Pays |
|
|
$1.35B |
-
|
US
|
|
|
- |
-
|
SE
|
|
|
- |
-
|
FR
|
|
|
- |
-
|
IT
|
|
|
$26.37M |
-
|
US
|
